A Pill Matched the Injectables in Psoriatic Arthritis — at $102,000 a Year, Sotyktu Is on the Clock, Not Skyrizi

At Week 16, 58% of ICOTYDE patients reached ACR20 and 29% reached ACR50, against 41% and 16% on placebo; in patients with qualifying skin involvement, IGA 0/1 was 57% versus 14% and PASI 90 was 37% versus 6%. By Week 24, after the placebo arm crossed over, ACR20 had climbed to 69% and ACR50 to 40%, with no new safety signals. The skin data is the commercially important part: biologic-like clearance in a pill is what reorders the treatment sequence.

ICOTYDE costs about $8,505 per 30-day supply at cash prices, roughly $102,000 a year. Novartis lists Cosentyx at $8,492.03 a month, about $101,900 annually, and AbbVie publishes $23,838.42 per 150 mg Skyrizi dose given every three months, about $95,400 a year. The pill is not cheaper than the injectables — it lands inside their price umbrella rather than underneath it.

What that pricing does to the economics matters more than what it does to the headline. An injectable carries a nurse visit, a cold chain, self-injection training and a specialty-pharmacy dispense; a once-daily pill carries none of them. Compress that administrative premium and a $100,000 biologic starts to look like a $100,000 pill — while the $74,000 oral that payers already prefer when efficacy allows loses the argument for existing. The repricing lands on the cheap oral tier first, not on the biologics.

Bristol Myers Squibb won approval for Sotyktu in psoriatic arthritis on March 6, 2026, and the product did $100 million worldwide in Q3, up 26%. Amgen's Otezla, the incumbent low-cost oral, fell 18% to $481 million on 13% lower volume. Both now share a market with a pill carrying biologic-comparable efficacy at a biologic-scale price.

Protagonist Therapeutics discovered the peptide and licensed it to Johnson & Johnson, which ran every trial after Phase 1 and owns commercialization. It earns 6% to 10% of global net sales, blending to about 7.25% at $4 billion of annual sales, with up to $580 million of further regulatory and sales milestones. Johnson & Johnson has paid $387.5 million in upfront and milestone payments since 2017 and has not yet triggered the second-indication payment.

The comparison is the point: on Takeda's rusfertide, Protagonist keeps roughly 21 cents of every sales dollar at $1.5 billion of sales; on J&J's icotrokinra it keeps about seven. Scale is what compresses royalty rates, which tells you the licensee keeps roughly 93 cents of every icotrokinra dollar — so a psoriatic arthritis approval is worth far more to Johnson & Johnson's shareholders than to the licensor's.

Specialty pharmacy is where a $102,000 injectable is dispensed and managed, with a service fee attached to each script and a rebate negotiation attached to each plan. An oral at the same price needs less of that apparatus. McKesson turned $111.0 billion of quarterly revenue into $3.96 billion of gross profit in its September 2026 quarter, a 3.6% margin; The Cigna Group's trailing gross profit is $29.4 billion on $286.3 billion of revenue, about 10.3%. Neither business changes size when a biologic becomes a pill, but the economics of the pharmacy benefit do.

The read-through for the channel is modest but specific: volume migrates from the specialty script to the pharmacy script, and rebate economics follow the molecule rather than the vial. Neither distributor nor benefit manager is a short or a long on this readout; the useful signal is which of them reports specialty-script growth decelerating in 2027.

The thesis in one line: an oral with biologic-comparable efficacy, priced at biologic parity, pulls the case for injectables down until the cheaper oral tier becomes indefensible. That is a volume-and-mix story for Johnson & Johnson and its licensor, a launch risk for Bristol Myers Squibb, and a rounding error for AbbVie and Novartis over the next two years.

Three facts would falsify the call: an active-comparator trial showing icotrokinra behind Skyrizi on joint response; ICONIC-PsA 2 failing to replicate in biologic-experienced patients; or a payer decision keeping the pill behind step therapy that requires a biologic first. None of the three can be settled by the Nov. 7 data, which is why the tape has not settled either.